Compound’s Pre-Screening of <i>Withania somnifera</i>, <i>Bacopa monnieri</i>and <i>Centella asiatica</i>Extracts  

作　　者：Steffi Witter Georg Arju Marina Junusova Maria Kuhtinskaja Ago Samoson Raiker Witter Raivo Vilu Steffi Witter;Georg Arju;Marina Junusova;Maria Kuhtinskaja;Ago Samoson;Raiker Witter;Raivo Vilu(Department of Health Technologies, Tallinn University of Technology, Tallinn, Estonia;Competence Center of Food and Fermentation Technology (TFTAK), Tallinn, Estonia;Department of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia;Institute of Nanotechnology, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany;Institute for Quantum Optics, Ulm University, Ulm, Germany)

机构地区：[1]Department of Health Technologies, Tallinn University of Technology, Tallinn, Estonia [2]Competence Center of Food and Fermentation Technology (TFTAK), Tallinn, Estonia [3]Department of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia [4]Institute of Nanotechnology, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany [5]Institute for Quantum Optics, Ulm University, Ulm, Germany

出　　处：《Journal of Biosciences and Medicines》2020年第9期80-98,共19页生物科学与医学（英文）

摘　　要：Spectral fluorescence signature, Gas Chromatography-Mass Spectrometry and Liquid Chromatography-Mass Spectrometry for identification of chemical and bioactive compounds were applied to study the plant extracts of <em>Withania somnifera</em>, <em>Centella asiatica </em>and <em>Bacopa monnieri </em>which are related to the possible treatment of mental diseases as Alzheimer, Parkinson and Depression. These plants are known for different positive phytotherapeutic effects on the human brain without negative post-, adverse or after effects to the treated individuals, and have been recommended in several medical studies. Therefore, we selected these plants for further analysis, based on the inhibition results of <em>in vitro</em> Amyloid Beta fibrillation tests made by previous measurements. With this study a first screening of the complex plant extract mixtures was performed, to get an initial overview about known and unknown ingredients. In all three plants, similar main compounds were identified, however in different quality and quantity. These may provide substantial information on which compound combinations might be mainly responsible for the positive effects and should be further investigated being responsible for reducing the fibrillation process of Amyloid Beta.Spectral fluorescence signature, Gas Chromatography-Mass Spectrometry and Liquid Chromatography-Mass Spectrometry for identification of chemical and bioactive compounds were applied to study the plant extracts of <em>Withania somnifera</em>, <em>Centella asiatica </em>and <em>Bacopa monnieri </em>which are related to the possible treatment of mental diseases as Alzheimer, Parkinson and Depression. These plants are known for different positive phytotherapeutic effects on the human brain without negative post-, adverse or after effects to the treated individuals, and have been recommended in several medical studies. Therefore, we selected these plants for further analysis, based on the inhibition results of <em>in vitro</em> Amyloid Beta fibrillation tests made by previous measurements. With this study a first screening of the complex plant extract mixtures was performed, to get an initial overview about known and unknown ingredients. In all three plants, similar main compounds were identified, however in different quality and quantity. These may provide substantial information on which compound combinations might be mainly responsible for the positive effects and should be further investigated being responsible for reducing the fibrillation process of Amyloid Beta.

关 键 词：Gas Chromatography-Mass Spectrometry Liquid Chromatography-Mass Spectrometry Principal Component Analysis Spectra Fluorescence Signature EXTRACTS Withania somnifera Bacopa monnieri Centella asiatica 

分 类 号：R74[医药卫生—神经病学与精神病学]